To compare the diagnostic performance of real-time maximum liver capacity (LiMAx) with dynamic contrast-enhanced ultrasound (CEUS)-based liver microcirculation.
MATERIALS AND METHODS:
23 patients underwent liver function capacity (LiMAx) test and consecutive or previous CEUS examinations. A bolus injection of 1.4 ml sulfur hexafluoride microbubbles was administered for CEUS measurements (1–6 MHz) and quantitative perfusion analysis (TIC) was performed with an integrated perfusion software using stored cine-loops. Two perfusion-parameters, time to peak (TtoP) and area under the curve (Area), were evaluated in liver parenchyma and portal vein using TIC analysis.
To compare quantification parameters, patients were classified in patients representing a healthy population (LiMAx value >315 μg/kg/h) and those representing patients with liver disease (LiMAx value <315 μg/kg/h).
RESULTS:
Comparing perfusion parameters derived from portal vein measurements, TtoP and Area were higher in patients with normal liver function TtoP: 25.0±8.4 s, Area: 1483±920 a.u. compared to patients with impaired liver function TtoP: 22.4±14.0 s; Area 1351±1212 a.u. This difference however was not statistically significant (p = 0.52, p = 0.48).
In parameters derived from measurements in liver parenchyma TtoP was higher (38.5±11.3 s) and Area was lower (999±632 a.u.) in patients with normal liver function compared to patients with impaired liver function (TtoP; 30.6±11.0 s, p = 0.156; Area: 1202±719 a.u.) (p = 0.16, p = 0.56).
In a simple linear regression model, none of the perfusion parameters measured in portal vein (TtoP portal, Area portal) and liver parenchyma (TtoP liver, Area liver) correlated significantly with respective LiMAx values (p = 0.194–0.950).
CONCLUSION:
Within the framework of this study, CEUS-based perfusion parameters were not able to assess severity of liver disease, assessed with LiMAx- test.
Ethical guidelines for publication in Clinical Hemorheology and Microcirculation: Update 2016, Clin Hemorheol Microcirc63 (2016), 1–2.
2.
BatallerR. and BrennerD.A., Liver fibrosis, J Clin Invest115 (2005), 209–218.
3.
BernatikT., StrobelD., HahnE.G. and BeckerD., Doppler measurements: A surrogate marker of liver fibrosis?Eur J Gastroenterol Hepatol14 (2002), 383–387.
4.
BolognesiM., SacerdotiD., MescoliC., BombonatoG., CilloU., MerendaR., GiacomelliL., MerkelC., RuggeM. and GattaA., Different hemodynamic patterns of alcoholic and viral endstage cirrhosis: Analysis of explanted liver weight, degree of fibrosis and splanchnic Doppler parameters, Scand J Gastroenterol42 (2007), 256–262.
5.
BoschJ., Vascular deterioration in cirrhosis: The big picture, J Clin Gastroenterol41(Suppl 3) (2007), S247–253.
6.
BurraP. and MasierA., Dynamic tests to study liver function, Eur Rev Med Pharmacol Sci8 (2004), 19–21.
7.
Cichoz-LachH., CelinskiK. and SlomkaM., and Kasztelan-SzczerbinskaB., Pathophysiology of portal hypertension. J Physiol Pharmacol, 59(Suppl 2) (2008), 231–238.
8.
ClavienP.A., PetrowskyH., DeOliveiraM.L. and GrafR., Strategies for safer liver surgery and partial liver transplantation, N Engl J Med356 (2007), 1545–1559.
9.
ClevertD.A., D’AnastasiM. and JungE.M., Contrast-enhanced ultrasound and microcirculation: Efficiency through dynamics–current developments, Clin Hemorheol Microcirc53 (2013), 171–186.
10.
Di LelioA., CestariC., LomazziA. and BerettaL., Cirrhosis: Diagnosis with sonographic study of the liver surface, Radiology172 (1989), 389–392.
11.
GaianiS., GramantieriL., VenturoliN., PiscagliaF., SiringoS., D’ErricoA., ZironiG., GrigioniW. and BolondiL., What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy, J Hepatol27 (1997), 979–985.
12.
GotoY., OkudaK., AkasuG., KinoshitaH. and TanakaH., Noninvasive diagnosis of compensated cirrhosis using an analysis of the time-intensity curve portal vein slope gradient on contrast-enhanced ultrasonography, Surg Today44 (2014), 1496–1505.
13.
GrierS., LimA.K., PatelN., CobboldJ.F., ThomasH.C., CoxI.J. and Taylor-RobinsonS.D., Role of microbubble ultrasound contrast agents in the non-invasive assessment of chronic hepatitis C-related liver disease, World J Gastroenterol12 (2006), 3461–3465.
14.
GuglielmiA., RuzzenenteA., ConciS., ValdegamberiA. and IaconoC., How much remnant is enough in liver resection?Dig Surg29 (2012), 6–17.
15.
HaimerlM., JungE.M., BeyerL.P., PreglerB., DollingerM., SieronD., NiessenC., StroszczynskiC. and WiggermannP., Chronic liver disease: Correlation of CEUS-based microperfusion and indocyanine green clearance, Clin Hemorheol Microcirc61 (2015), 195–204.
16.
JungE.M., ClevertD.A., SchreyerA.G., SchmittS., RennertJ., KubaleR., FeuerbachS. and JungF., Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study, World J Gastroenterol13 (2007), 6356–6364.
17.
LimA.K., PatelN., EckersleyR.J., KuoY.T., GoldinR.D., ThomasH.C., CosgroveD.O., Taylor-RobinsonS.D. and BlomleyM.J., Can Doppler sonography grade the severity of hepatitis C-related liver disease?, AJR Am J Roentgenol184 (2005), 1848–1853.
18.
LimA.K., Taylor-RobinsonS.D., PatelN., EckersleyR.J., GoldinR.D., HamiltonG., FosterG.R., ThomasH.C., CosgroveD.O. and BlomleyM.J., Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C, Gut54 (2005), 128–133.
19.
LockJ.F., WestphalT., RubinT., MalinowskiM., SchulzA., JaraM., BednarschJ. and StockmannM., LiMAx Test Improves Diagnosis of Chemotherapy-Associated Liver Injury Before Resection of Colorectal Liver Metastases, Ann Surg Oncol (2017).
20.
Morris-StiffG., GomezD. and PrasadR., Quantitative assessment of hepatic function and its relevance to the liver surgeon, J Gastrointest Surg13 (2009), 374–385.
21.
ObertiF., ValsesiaE., PiletteC., RousseletM.C., BedossaP., AubeC., GalloisY., RiffletH., MaigaM.Y., Penneau-FontbonneD. and CalesP., Noninvasive diagnosis of hepatic fibrosis or cirrhosis, Gastroenterology113 (1997), 1609–1616.
22.
PiscagliaF., GaianiS., ZironiG., GramantieriL., CasaliA., SiringoS., SerraC. and BolondiL., Intra- and extrahepatic arterial resistances in chronic hepatitis and liver cirrhosis, Ultrasound Med Biol23 (1997), 675–682.
RiberoD., AmisanoM., BertuzzoF., LangellaS. and Lo TesoriereR., FerreroA., ReggeD. and CapussottiL., Measured versus estimated total liver volume to preoperatively assess the adequacy of the future liver remnant: Which method should we use?, Ann Surg258 (2013), 801–806; discussion 806–807;.
25.
RidolfiF., AbbattistaT., BusilacchiP. and BrunelliE., Contrast-enhanced ultrasound evaluation of hepatic microvascular changes in liver diseases, World J Gastroenterol18 (2012), 5225–5230.
26.
RidolfiF., AbbattistaT., MariniF., VedovelliA., QuagliariniP., BusilacchiP. and BrunelliE., Contrast-enhanced ultrasound to evaluate the severity of chronic hepatitis C, Dig Liver Dis39 (2007), 929–935.
27.
SchellhaasB., WaldnerM.J., R.S.G.O., VitaliF. and KielischC., PfeiferL., StrobelD., JankaR., NeurathM.F. and WildnerD., Diagnostic accuracy and interobserver variability of Dynamic Vascular Pattern (DVP) in primary liver malignancies - A simple semiquantitative tool for the analysis of contrast enhancement patterns, Clin Hemorheol Microcirc (2017).
28.
SearleJ., MendelsonR., ZelescoM., SanfordJ., ChengW., McKinstryC. and RamsayD., Non-invasive prediction of the degree of liver fibrosis in patients with hepatitis C using an ultrasound contrast agent. A pilot study, J Med Imaging Radiat Oncol52 (2008), 130–133.
29.
StaubF., Tournoux-FaconC., RoumyJ., ChaigneauC., Morichaut-BeauchantM., LevillainP., PrevostC., AubeC., LebigotJ., ObertiF., GaltierJ.B., LaumonierH., TrillaudH., BernardP.H., BlancJ.F., SironneauS., MachetF., DrouillardJ. and de LedinghenV., CouzigouP., FoucherP., CasteraL., TranquardF., BacqY., d’AlterocheL., IngrandP. and TasuJ.P., Liver fibrosis staging with contrast-enhanced ultrasonography: Prospective multicenter study compared with METAVIR scoring, Eur Radiol19 (2009), 1991–1997.
30.
StockmannM., LockJ.F., MalinowskiM., NiehuesS.M., SeehoferD. and NeuhausP., The LiMAx test: A new liver function test for predicting postoperative outcome in liver surgery, HPB (Oxford)12 (2010), 139–146.
31.
StockmannM., LockJ.F., RieckeB., HeyneK., MartusP., FrickeM., LehmannS., NiehuesS.M., SchwabeM., LemkeA.J. and NeuhausP., Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity, Ann Surg250 (2009), 119–125.
ThabutD. and ShahV., Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: New targets for the treatment of portal hypertension?, J Hepatol53 (2010), 976–980.
34.
WibmerA., AliyaQ., SteiningerR., TraunerM., MareschJ., MuhlbacherF. and Ba-SsalamahA., Liver transplantation: Impaired biliary excretion of gadoxate is associated with an inferior 1-year retransplantation-free survival, Invest Radiol47 (2012), 353–358.
YueW.W., WangS., XuH.X., SunL.P., GuoL.H., BoX.W., LiX.L., ZhaoC.K., WangD. and LiuB.J., Parametric imaging with contrast-enhanced ultrasound for differentiating hepatocellular carcinoma from metastatic liver cancer, Clin Hemorheol Microcirc64 (2016), 177–188.
37.
ZoliM., MagalottiD., BianchiG., GhigiG., OrlandiniC., GrimaldiM., MarchesiniG. and PisiE., Functional hepatic flow and Doppler-assessed total hepatic flow in control subjects and in patients with cirrhosis, J Hepatol23 (1995), 129–134.
